Alvine Pharmaceuticals, Inc.
http://www.alvinepharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alvine Pharmaceuticals, Inc.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
Trials In Focus: Joint Venture Aims To Simplify Cell Therapy Trials For Smaller Players
CTMC CEO Jason Bock talked to Scrip about the venture between MD Anderson and National Resilience, which provides manufacturing, process development and regulatory support for small cell therapy developers’ preclinical and clinical proof-of-concept studies. Meanwhile, Verge Genomics initiated a Phase Ib study of its AI-discovered drug for ALS; EyePoint and Aviceda dosed patients in their Phase II DME trials; Parexel teamed up with a non-profit cancer research group in Japan; and BARDA selected PPD to run its Phase II platform trial for ARDS.
A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Health Care Continuum
As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice